T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.45B |
| 2 |
JPMorgan Chase
JPM
|
+$2.22B |
| 3 |
Atlassian
TEAM
|
+$2.08B |
| 4 |
NVIDIA
NVDA
|
+$1.81B |
| 5 |
Apple
AAPL
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.24B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.08B |
| 3 |
Microsoft
MSFT
|
+$2.68B |
| 4 |
Wells Fargo
WFC
|
+$1.93B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.86B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.79% |
| 2 | Healthcare | 17.19% |
| 3 | Consumer Discretionary | 15.16% |
| 4 | Financials | 10.74% |
| 5 | Communication Services | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FMTX
2751
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $156K | ﹤0.01% |
16,795
+800
| +5% | +$8.52K |
|
|
ONL
2752
Orion Office REIT
ONL
$161M
| $155K | ﹤0.01% |
11,076
-21,959
| -66% | -$370K |
|
2753
Vipshop
VIPS
$6.8B
| $154K | ﹤0.01% |
17,100
+3,800
| +29% | +$33.5K |
|
2754
Vital Farms
VITL
$498M
| $153K | ﹤0.01% |
12,368
+500
| +4% | +$7.51K |
|
2755
Innodata
INOD
$2.03B
| $152K | ﹤0.01% |
21,800
| – | – |
|
|
LUCK
2756
Lucky Strike Entertainment
LUCK
$930M
| $152K | ﹤0.01% |
+14,300
| New | +$132K |
|
|
EXTN
2757
DELISTED
Exterran Corporation
EXTN
| $151K | ﹤0.01% |
24,300
-5,200
| -18% | -$27.7K |
|
2758
N-able
NABL
$695M
| $150K | ﹤0.01% |
16,443
+621
| +4% | +$6.54K |
|
2759
Rhythm Pharmaceuticals
RYTM
$7.99B
| $149K | ﹤0.01% |
+12,900
| New | +$113K |
|
2760
Axogen
AXGN
$2.58B
| $147K | ﹤0.01% |
18,563
+7,683
| +71% | +$66.4K |
|
|
CHMI
2761
Cherry Hill Mortgage Investment Corp
CHMI
$108M
| $147K | ﹤0.01% |
19,030
| – | – |
|
2762
1-800-Flowers.com
FLWS
$261M
| $147K | ﹤0.01% |
11,510
-18,717
| -62% | -$322K |
|
2763
iBio
IBIO
$69.5M
| $147K | ﹤0.01% |
686
+12
| +2% | +$2.51K |
|
|
OTIC
2764
DELISTED
Otonomy, Inc.
OTIC
| $147K | ﹤0.01% |
61,400
| – | – |
|
|
ASXC
2765
DELISTED
Asensus Surgical, Inc.
ASXC
| $145K | ﹤0.01% |
230,941
+33,100
| +17% | +$25.5K |
|
|
PRVB
2766
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $145K | ﹤0.01% |
+19,876
| New | +$119K |
|
|
MYOV
2767
DELISTED
Myovant Sciences Ltd.
MYOV
| $145K | ﹤0.01% |
10,900
| – | – |
|
2768
Cadiz
CDZI
$295M
| $144K | ﹤0.01% |
69,556
+5,000
| +8% | +$12.6K |
|
2769
Noodles & Co
NDLS
$100M
| $144K | ﹤0.01% |
3,018
+108
| +4% | +$6.63K |
|
2770
Angi Inc
ANGI
$196M
| $143K | ﹤0.01% |
2,520
-480
| -16% | -$35K |
|
|
TFFP
2771
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
| $143K | ﹤0.01% |
908
| – | – |
|
2772
Sportsman's Warehouse
SPWH
$46.8M
| $142K | ﹤0.01% |
13,241
+948
| +8% | +$10.6K |
|
|
EMKR
2773
DELISTED
Emcore Corp
EMKR
| $141K | ﹤0.01% |
3,802
+100
| +3% | +$4.79K |
|
2774
Smartbird Inc
BIRD
$31.2M
| $140K | ﹤0.01% |
1,163
-450,444
| -100% | -$88.6M |
|
|
HARP
2775
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $140K | ﹤0.01% |
2,823
+450
| +19% | +$23.3K |
|
Similar funds
T. Rowe Price Associates's Q1 2022 Portfolio in Review
As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
- T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
- T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
- T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
- T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
- T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.